Intercept: a $500M philanthropic bet to make colds and flu history

Intercept is a new $500 million philanthropic initiative aiming to drastically cut—and eventually eliminate—common respiratory infections like colds and influenza, drawing an explicit analogy to how clean-water infrastructure and pharmaceutical advances tamed cholera and typhoid a century ago. The effort grew out of a 2024 symposium hosted at Stripe with roughly 40 scientists, pharma R&D leaders, biotech investors, and regulators, who concluded the goal is technically hard but increasingly tractable thanks to new platform technologies, better immunology, large biological datasets, and protein-design tools. The two historical blockers were the sheer diversity of mutating viral strains and chronic underfunding, since broad-spectrum work fits neither philanthropic nor commercial models well—COVID briefly reversed that, but the momentum faded.

The initiative funds two complementary technology bets. Broad-spectrum preventatives (BSPs)—a shot, nasal spray, or pill—would defend against many virus families at once, targeting prevention of over 75% of symptomatic infections with a realistic path to about 60% uptake; the core challenge is staying broad without triggering side effects from over-stimulating the immune system. Because no single intervention can reach the population-level protection needed (eliminating an R0-3 virus requires roughly 67% coverage), BSPs are paired with air-cleaning technologies (ACTs) like filtration and far-UVC light to reduce airborne virions in dense settings such as offices, schools, and transit. Neither approach suffices alone at achievable adoption levels, but combined they could push effective transmission below the elimination threshold.

The pitch leans on a reframing of respiratory illness as a serious, underestimated burden rather than a nuisance: people lose roughly 15–25 days a year to it, global productivity losses run near $600B annually, and emerging research links infections to elevated long-term risks of asthma, heart attack, dementia, and other conditions. The framing also has a biosecurity dimension—broad protection plus air disinfection would serve as a first line of defense against both natural pandemics and engineered biological threats. The data on long-term harms remains early and associative, and the project is a bet that focused capital can finish work the market abandoned once strain-specific COVID vaccines arrived.